CADL · Candel Therapeutics, Inc.
$10.35
+0.17 (+1.65%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$832.52M
Shares
76.52M
Volume · Oct 5
543.56K
Avg daily vol (3M)
1.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.18
Open$10.29
Day$10.03–10.37
52W close$4.42–13.75
Avg vol 30d1.2M
Short int12.3M · 16.1% float · 10.3d
Short vol61%
Last earningsMay 20, 2026
DataJul 2021–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Feb 23, 2028
Est · unconfirmed
· in 72 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$125,000
Trailing 12 months
Net income (TTM)
−$88.53M
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
-27,777.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+44.0%
Year over year · more shares
Price change (1Y)
+88.2%
Trailing year
Short interest
16.1%
Latest settlement · 10.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+28%
above
Price vs 50-day avg
−11%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
+109%
trailing
YTD return
+80%
this year
Relative strength
+97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +39 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.13% of float · ▲ +0.6% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
138 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+59%
Y/Y
Free cash flow
$-38.9M
Balance sheet
$82.1M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+28%
Bullish
Price vs 50-day avg
−11%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +39 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.13% of float · ▲ +0.6% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
138 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $10 · 62%
Range high $14
vs 200-day avg +28%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CADL
this stock
Candel Therapeutics, Inc.
|
$832.52M | +80.2% | +0.0% | — | 16.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CADL | -7.6% | -21.5% | +109.0% | -2.5% | +80.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.4% | -21.1% | +96.9% | -3.4% | +67.3% |